Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new ...

Mirvetuximab soravtansine (Elahere) is an antibody-drug conjugate designed to treat ovarian cancer. It works by binding to folate receptor-alpha (FRα). This binding delivers a potent anticancer drug ...

The FDA has granted orphan drug designation to namodenoson (CF102) in pancreatic cancer. Orphan drug designation provides Can ...

Jacob E. Berchuck, MD, discussed research behind using a blood-based liquid biopsy in prostate cancer and findings presented ...

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of ...

The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been ...

The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been ...

The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...

Erika P. Hamilton, MD, discusses the patient population with breast cancer enrolled in the TROPION-PanTumor01 trial in ...

David Braun, MD, PhD, discusses how biomarkers are evolving for the treatment of renal cell carcinoma. Biomarkers play a crucial role in the management of renal cell carcinoma (RCC). These biological ...